Latest updates for Arsvx
Fresh curated links around ARSVX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- AMG River Road Small Cap Value Fund Q2 2026 Commentary
- Archer Limited (ARHVF) Q2 2026 Earnings Call Prepared Remarks Transcript
- Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
seekingalpha.com
/1 week ago
Archer Limited (ARHVF) Q2 2026 Earnings Call Prepared Remarks Transcript
finance.yahoo.com
/2 weeks ago
Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases
seekingalpha.com
/3 weeks ago
argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow
seekingalpha.com
/3 weeks ago
argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
seekingalpha.com
/3 weeks ago
Antero Resources Corporation (AR) Q2 2026 Earnings Call Transcript
seekingalpha.com
/6 days ago
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy
qchron.com
/1 week ago
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord.
seekingalpha.com
/4 weeks ago
Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions
newswire.com
/1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
fool.com
/1 month ago
What This $1.1 Million Insider Sale at Accelerant Means for Investors
Executed under a pre-arranged Rule 10b5-1 plan, the transaction reduces Radke's stake by just 0.28%, leaving him with ~28.6 million shares worth $379 million.
biopharmadive.com
/6 days ago
Argenx jumps on Phase 3 data for blockbuster Vyvgart
The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.
seekingalpha.com
/1 week ago
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch
seekingalpha.com
/4 weeks ago
Grupo Aeroportuario del Sureste, S. A. B. de C. V. (ASR) Q2 2026 Earnings Call Transcript
medium.com
/1 week ago
From Vision to Execution: AR$H Enters Its Next Chapter
Every meaningful project begins with a vision.Continue reading on Medium »
seekingalpha.com
/1 week ago
Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
fool.com
/1 week ago
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Arsvx
seekingalpha.com
Recent coverage from public sources
Public source
finance.yahoo.com
Recent coverage from public sources
Public source
medium.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source